# US 2024/0002818 A1 · Mammalian mobile element compositions, systems and therapeutic applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002818 A1
- Document ID: US20240002818A1
- Status: Published application
- Kind: A1
- Application number: 18/037,937
- Filed: 2021-11-24
- Published: 2024-01-04
- Earliest claimed: 2020-11-24
- Assignees: Saliogen Therapeutics, Inc.
- Applicants: Saliogen Therapeutics, Inc.
- Inventors: Joseph J. HIGGINS; Ray TABIBIAZAR
- Web page: https://patentgrep.com/patent/US20240002818A1

## CPC

- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/85: for animal cells
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0033: {the non-active part being non-polymeric}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Recombinant mammalian helper enzymes for targeted transposition are described. The mammalian helper enzymes and corresponding donor DNAs can be used, e.g., for gene therapy.

## Claims

### Claim 1

A composition comprising:
(a) a recombinant helper enzyme, or a nucleotide sequence encoding the same, having gene cleavage (Exc) and/or gene integration (Int) activity and at least about 90% identity to the amino acid sequence of SEQ ID NO: 2, and/or
(b) a gene transfer construct comprises a vector comprising a donor DNA comprising left and right end sequences recognized by the recombinant helper enzyme, the left and right end sequences having at least about 90% identity to the nucleotide sequences of SEQ ID NO: 11 and SEQ ID NO: 16.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the helper enzyme has at least about 95%, or at least about 96%, at least about 97%, at least about 98%, at least about 99% identity to the amino acid sequence SEQ ID NO: 2.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or claim 2, wherein the helper enzyme has one or more mutations which confer hyperactivity.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1 to 3, wherein the helper enzyme has an amino acid sequence having mutations at positions which correspond to at least one of S8P and G17R mutations relative to the amino acid sequence of SEQ ID NO: 2 or a functional equivalent thereof.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the helper enzyme has the nucleotide sequence having at least about 90% identity to SEQ ID NO: 1 or a codon-optimized form thereof.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the helper enzyme has the nucleotide sequence having at least about 95%, or at least about 96%, at least about 97%, at least about 98%, at least about 99% identity to SEQ ID NO: 1, or a codon-optimized form thereof.

### Claim 7 (depends on 5, 6)

The composition of claim 5 or 6, wherein the nucleotide sequence comprises a thymine (T) at position 1933 of SEQ ID NO: 1, or a position corresponding thereto of SEQ ID NO: 1.

### Claim 8

The composition of any one of the above claims, wherein the composition comprises a gene transfer construct.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the gene transfer construct comprises a vector comprising a donor DNA comprising left and right end sequences recognized by the helper enzyme.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the end sequences are selected from Pteropus vampyrus ends, MER75, MER75A, MER75B, and MER85.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the end sequences are selected from nucleotide sequences of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, or a nucleotide sequence having at least about 90% identity thereto.

### Claim 12 (depends on 9, 10, 11)

The composition of any one of claims 9 to 11, wherein one or more of the end sequences are optionally flanked by a TTAA sequence.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 11, and wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 11 is positioned at the 5′ end of the donor DNA.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 16, and wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 16 is positioned at the 3′ end of the donor DNA.

### Claim 15 (depends on 13, 14)

The composition of claim 13 or claim 14, wherein the end sequences are optionally flanked by a TTAA sequence.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 12, and wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 12 is positioned at the 5′ end of the donor DNA.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 17, and wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 17 is positioned at the 3′ end of the donor DNA.

### Claim 18 (depends on 16, 17)

The composition of claim 16 or claim 17, wherein the end sequences are optionally flanked by a TTAA sequence.

### Claim 19 (depends on 11)

The composition of claim 11, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 13, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 13 is positioned at the 5′ end of the donor DNA.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 18, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 18 is positioned at the 3′ end of the donor DNA.

### Claim 21 (depends on 19, 20)

The composition of claim 19 or claim 20, wherein the end sequences are optionally flanked by a TTAA sequence.

### Claim 22 (depends on 11)

The composition of claim 11, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 14, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 14 is positioned at the 5′ end of the donor DNA.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 19, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 19 is positioned at the 3′ end of the donor DNA.

### Claim 24 (depends on 22, 23)

The composition of claim 22 or claim 23, wherein the end sequences are optionally flanked by a TTAA sequence.

### Claim 25 (depends on 11)

The composition of claim 11, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 15, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 15 is positioned at the 5′ end of the donor DNA.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 20, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 20 is positioned at the 3′ end of the donor DNA.

### Claim 27 (depends on 25, 26)

The composition of claim 25 or claim 26, wherein the end sequences are optionally flanked by a TTAA sequence.

### Claim 28

A composition comprising:
(a) a recombinant helper enzyme, or a nucleotide sequence encoding the same, having gene cleavage (Exc) and/or gene integration (Int) activity and at least about 90% identity to the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, and
(b) a gene transfer construct comprises a vector comprising a donor DNA comprising left and right end sequences recognized by the recombinant helper enzyme, the end sequences having at least about 90% identity to the nucleotide sequences of SEQ ID NO: 11 and SEQ ID NO: 16.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The composition of any one of claims 1-28, wherein the composition comprises a targeting element.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The composition of any one of claims 1-29, wherein the composition is capable of inserting a donor comprising a transgene in a genomic safe harbor site (GSHS).

### Claim 31 (depends on 30)

The composition of claim 30, wherein the binding of a GSHS of a nucleic acid molecule in a mammalian cell is with high target specificity.

### Claim 32 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein the targeting element is able to direct a transposition machinery to the GSHS of a nucleic acid molecule in a mammalian cell.

### Claim 33 (depends on 30, 31, 32)

The composition of any one of claims 30-32, wherein the GSHS is in an open chromatin location in a chromosome.

### Claim 34 (depends on 30, 31, 32, 33)

The composition of any one of claims 30-33, wherein the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C—C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The composition of any one of claims 30-34, wherein the GSHS is an adeno-associated virus site 1 (AAVS1).

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The composition of any one of claims 30-35, wherein the GSHS is a human Rosa26 locus.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 30-36, wherein the GSHS is located on human chromosome 2, 4, 6, 11, 17, 22, or X.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The composition of any one of claims 30-37, wherein the GSHS is selected from TALC1, TALC2, TALC3, TALC4, TALC5, TALC7, TALC8, AVS1, AVS2, AVS3, ROSA1, ROSA2, TALER1, TALER2, TALER3, TALER4, TALER5, SHCHR2-1, SHCHR2-2, SHCHR2-3, SHCHR2-4, SHCHR4-1, SHCHR4-2, SHCHR4-3, SHCHR6-1, SHCHR6-2, SHCHR6-3, SHCHR6-4, SHCHR10-1, SHCHR10-2, SHCHR10-3, SHCHR10-4, SHCHR10-5, SHCHR11-1, SHCHR11-2, SHCHR11-3, SHCHR17-1, SHCHR17-2, SHCHR17-3, and SHCHR17-4.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38)

The composition of any one of claims 30-38, wherein the targeting element comprises one or more of a Cas enzyme, which is optionally catalytically inactive and which is optionally associated with a guide RNA (gRNA), transcription activator-like effector (TALE) DNA binding domain (DBD), catalytically inactive Zinc finger, catalytically inactive transcription factor, catalytically inactive nickase, a transcriptional activator, a transcriptional repressor, a recombinase, a DNA methyltransferase, a histone methyltransferase, and a paternally expressed gene 10 (PEG10).

### Claim 40 (depends on 39)

The composition of claim 39, wherein the targeting element comprises a TALE DBD.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the TALE DBD comprises one or more repeat sequences.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the TALE DBD comprises about 14, or about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences.

### Claim 43 (depends on 41, 42)

The composition of claim 41 or claim 42, wherein the repeat sequences each independently comprises about 33 or 34 amino acids.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the repeat sequences each independently comprises a repeat variable di-residue (RVD) at residue 12 or 13 of the 33 or 34 amino acids, respectively.

### Claim 45 (depends on 44)

The composition of claim 44, wherein the RVD recognizes one base pair in a target nucleic acid sequence.

### Claim 46 (depends on 44, 45)

The composition of claim 44 or claim 45, wherein the RVD recognizes a C residue in the target nucleic acid sequence and is selected from HD, N(gap), HA, ND, and HI.

### Claim 47 (depends on 44, 45)

The composition of claim 44 or claim 45, wherein the RVD recognizes a G residue in the target nucleic acid sequence and is selected from NN, NH, NK, HN, and NA.

### Claim 48 (depends on 44, 45)

The composition of claim 44 or claim 45, wherein the RVD recognizes an A residue in the target nucleic acid sequence and is selected from NI and NS.

### Claim 49 (depends on 44, 45)

The composition of claim 44 or claim 45, wherein the RVD recognizes a T residue in the target nucleic acid sequence and is selected from NG, HG, H(gap), and IG.

### Claim 50 (depends on 39)

The composition of claim 39, wherein the targeting element comprises a Cas9 enzyme associated with a gRNA.

### Claim 51 (depends on 50)

The composition of claim 50, wherein the Cas9 enzyme associated with a gRNA comprises a catalytically inactive dCas9 associated with a gRNA.

### Claim 52 (depends on 51)

The composition of claim 51, wherein the catalytically inactive dCas9 comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 21 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 22 or a codon-optimized form thereof.

### Claim 53 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 29-52, wherein the targeting element comprises a Cas12 enzyme associated with a gRNA.

### Claim 54 (depends on 53)

The composition of claim 53, wherein the targeting element comprises a catalytically inactive Cas12 associated with a gRNA, optionally wherein the catalytically inactive Cas12 is dCas12j or dCas12a.

### Claim 55 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 29-54, wherein the targeting element comprises: a gRNA of or comprising a sequence of TABLE 3A-3F, or a variant thereof; or a TALE DBD of or comprising a sequence of TABLE 4A-4F, or a variant thereof; or a ZNF of or comprising a sequence of TABLE 5A-5E, or a variant thereof.

### Claim 56 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition of any one of claims 29-55, wherein the targeting element comprises a nucleic acid binding component of a gene-editing system.

### Claim 57 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The composition of any one of claims 29-56, wherein the enzyme or variant thereof and the targeting element are connected.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the enzyme and the targeting element are fused to one another or linked via a linker to one another.

### Claim 59 (depends on 58)

The composition of claim 58, wherein the linker is a flexible linker.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the flexible linker is substantially comprised of glycine and serine residues, optionally wherein the flexible linker comprises (Gly4Ser)n, where n is an integer from 1-12.

### Claim 61 (depends on 60)

The composition of claim 60, wherein the flexible linker is of about 20, or about 30, or about 40, or about 50, or about 60 amino acid residues.

### Claim 62 (depends on 61)

The composition of claim 61, wherein the enzyme is directly fused to the N-terminus of the dCas9 enzyme.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The composition of any one of claims 1-62, wherein the enzyme or variant thereof is able to directly or indirectly cause transposition of a target gene.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The composition of any one of claims 1-63, wherein the enzyme or variant thereof is able to directly or indirectly interact and/or form a complex with one or more proteins or nucleic acids.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The composition of any one of claims 1-64, further comprising a nucleic acid encoding a donor comprising a transgene to be integrated.

### Claim 66 (depends on 65)

The composition of claim 65, wherein the transgene comprises a cargo nucleic acid sequence and a first and a second donor end sequences.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the cargo nucleic acid sequence is flanked by the first and the second donor end sequences.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The composition of any one of claims 1-67, wherein the enzyme or variant thereof is incorporated into a vector or a vector-like particle.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The composition of any one of claims 1-68, wherein the vector or a vector-like particle comprises one or more expression cassettes.

### Claim 70 (depends on 69)

The composition of claim 69, wherein the vector or a vector-like particle comprises one expression cassette.

### Claim 71 (depends on 70)

The composition of claim 70, wherein the expression cassette further comprises the enzyme or variant thereof, the transgene, the donor end sequences, or a combination thereof.

### Claim 72 (depends on 71)

The composition of claim 71, wherein the enzyme or variant thereof, the transgene, the donor end sequences, or a combination thereof are incorporated into one or more vectors or vector-like particles.

### Claim 73 (depends on 72)

The composition of claim 72, wherein the enzyme or variant thereof, the transgene, the donor end sequences, or combination thereof are incorporated into a same vector or vector-like particle.

### Claim 74 (depends on 72)

The composition of claim 72, wherein the enzyme or variant thereof, the transgene, the donor end sequences, or combination thereof is incorporated into different vectors vector-like particles.

### Claim 75 (depends on 68, 69, 70, 71, 72, 73, 74)

The composition of claim of any one of claims 68-74, wherein the vector or vector-like particle is nonviral.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The composition of any one of claims 1-75, wherein the composition comprises DNA, RNA, or both.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The composition of any one of claims 1-76, wherein the enzyme or variant thereof is in the form of RNA.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

A host cell comprising the composition any one of claims 1-77.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The composition of any one of claims 1-77, wherein the composition is encapsulated in a lipid nanoparticle (LNP).

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The composition of any one of claims 1-79, wherein the polynucleotide encoding the enzyme or variant thereof and the polynucleotide encoding the donor are in the form of the same LNP, optionally in a co-formulation.

### Claim 81 (depends on 79, 80)

The composition of claim 79 or claim 80, wherein the LNP comprises one or more lipids selected from 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), a cationic cholesterol derivative mixed with dimethylaminoethane-carbamoyl (DC-Chol), phosphatidylcholine (PC), triolein (glyceryl trioleate), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol −2000 (DMG-PEG 2K), and 1,2 distearol-sn-glycerol-3phosphocholine (DSPC) and/or comprising of one or more molecules selected from polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), and N-Acetylgalactosamine (GaINAc).

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

A method for inserting a gene into the genome of a cell, comprising contacting a cell with the composition of any one of claim 1-77 or 79-81 or host cell of claim 78.

### Claim 83 (depends on 82)

The method of claim 82, further comprising contacting the cell with a polynucleotide encoding a donor.

### Claim 84 (depends on 82, 83)

The method of claim 82 or claim 83, wherein the donor comprises a gene encoding a complete polypeptide.

### Claim 85 (depends on 82, 83, 84)

The method of any one of claims 82-84, wherein the donor comprises a gene which is defective or substantially absent in a disease state.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

A method for treating a disease or disorder ex vivo, comprising contacting a cell with the composition of any one of claim 1-77 or 79-85 or host cell of claim 78 and administering the cell to a subject in need thereof.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

A method for treating a disease or disorder in vivo, comprising administering the composition of any one of claim 1-77 or 79-86 or host cell of claim 78 to a subject in need thereof.
